Healthcare Costs Among Patients With CML Receiving Dasatinib or Nilotinib in a Commercial and Medicare Population
| Status: | Completed |
|---|---|
| Conditions: | Blood Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | February 2014 |
| End Date: | November 2014 |
Costs and Outcome Among Patients With Chronic Myelogenous Leukemia (CML) Receiving Dasatinib or Nilotinib as First or Second Line Therapy in a Commercial and Medicare Population
The purpose of this study is to examine the healthcare costs among patients with CML
receiving dasatinib or nilotinib as first line therapy in a commercially or Medicare insured
population.
receiving dasatinib or nilotinib as first line therapy in a commercially or Medicare insured
population.
For more information regarding BMS clinical trial participation, please visit
www.BMSStudyConnect.com
Inclusion Criteria:
- Age >18 years
- International Classification of Diseases, Ninth Revision, Clinical Modification
(ICD-9 CM) code for CML (205.1x)
- At least 2 prescriptions for dasatinib or nilotinib from July 1, 2008 to June 31,
2013
- Continuous eligibility for the 6 months pre- and post-index date (defined as the date
of first fill for dasatinib or nilotinib)
Exclusion Criteria:
- History of bone marrow or stem cell transplant as identified in the 6 month
pre-period
We found this trial at
1
site
Click here to add this to my saved trials
